Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-04-15 DOI:10.1080/21645515.2024.2333098

Aodi Huang, Xia Xu, Lin Tang, Lifang Huang, Jun Li, Xue Zhang, Jiajie Liu, Yang Zhou, Bingling Zhang, Lei Wang, Qian Zhang, Zemei Zhou, Yu Wang, Xiaoqi Wang, Qianqian Liu, Siyu Liu, Zundong Yin, Fuzhen Wang

引用次数: 0

Abstract

DTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae ...

查看原文本刊更多论文

家长对 DTaP-HBV-IPV-Hib 六价疫苗的接受程度和支付意愿：中国横断面调查

多年来，高收入国家一直使用 DTaP-HBV-IPV-Hib 六价疫苗来预防白喉、破伤风、百日咳、乙型肝炎、脊髓灰质炎和侵袭性流感嗜血杆菌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.